CRYBA1 and diabetes mellitus: We found that treatment with either MSI-1436 or AAV2-Cryba1 construct for 2 months following diabetes onset did reduce IL-6 and IL-1α levels (Fig. 7a, b) as well as capillary degeneration (arrows in Fig. 7k, l).